Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 16, 2022 16:49 ET | Source: Athira Pharma, Inc.

Athira Issues Statement in Response to Richard A. Kayne’s Suspension of His Proxy Contest

Athira Board Unanimously Recommends Shareholders Vote “FOR” its Highly Qualified Nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE proxy card BOTHELL, Wash., May 16,...
May 16, 2022 07:00 ET | Source: Athira Pharma, Inc.

Athira Pharma Presents Preclinical Data at the 2022 Peripheral Nerve Society (PNS) Annual Meeting

BOTHELL, Wash., May 16, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
May 12, 2022 16:05 ET | Source: Athira Pharma, Inc.

Athira Pharma Reports First Quarter 2022 Financial Results and Provides Pipeline and Business Updates

BOTHELL, Wash., May 12, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
May 11, 2022 16:15 ET | Source: Athira Pharma, Inc.

Athira Urges Shareholders to Support its Director Nominees at May 19 Annual Meeting

Urges Shareholders to Vote TODAY “FOR” Athira’s Highly Qualified, Independent Director Nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE Proxy Card BOTHELL, Wash., May ...
May 09, 2022 07:00 ET | Source: Athira Pharma, Inc.

Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease

– Study duration increased from 6 months to 18 months of open label treatment with fosgonimeton – BOTHELL, Wash., May 09, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late...
May 05, 2022 12:04 ET | Source: Athira Pharma, Inc.

Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Athira Shareholders Vote “FOR” All of Athira’s Highly Qualified Director Nominees

Joins Institutional Shareholder Services in Recommending a Vote on Athira’s WHITE Proxy Card Athira Urges Shareholders to Vote “FOR” Athira’s Highly Qualified, Independent Director Nominees – Joseph...
May 05, 2022 08:00 ET | Source: Athira Pharma, Inc.

Athira Mails Letter to Shareholders Emphasizing the Company’s Strong Position and Qualified Board as it Enters Pivotal Chapter

Urges Shareholders to Vote “FOR” Athira’s Highly Qualified, Independent Director Nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE Proxy Card BOTHELL, Wash., May ...
May 04, 2022 18:46 ET | Source: Athira Pharma, Inc.

Leading Independent Proxy Advisory Firm ISS Recommends that Athira Shareholders Vote on Athira’s WHITE Proxy Card

Athira Urges Shareholders to Vote “FOR” Athira’s Highly Qualified, Independent Director Nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE Proxy Card Today BOTHELL,...
April 26, 2022 08:00 ET | Source: Athira Pharma, Inc.

Athira Files Investor Presentation Highlighting Successful Execution of its Strategy and Highly Qualified Board and Leadership

Urges shareholders to vote “FOR” Athira’s highly qualified, independent director nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE proxy card BOTHELL, Wash., April ...
April 20, 2022 09:02 ET | Source: Athira Pharma, Inc.

Athira Mails Letter to Shareholders Highlighting the Strength of its Board and Record of Deliberate Board Refreshment

Urges shareholders to vote “FOR” Athira’s highly qualified, independent director nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE proxy card BOTHELL, Wash., April 20,...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right